Key result
null
Why the study?
Amiodarone is commonly used to treat atrial and ventricular fibrillations but can cause pulmonary fibrosis, prompting evaluation of whether cannabinoid (O-2545) can attenuate this toxicity.
Does cannabinoid (O-2545) attenuate amiodarone-induced pulmonary fibrosis in male Wistar rats?
Does cannabinoid (O-2545) attenuate amiodarone-induced pulmonary fibrosis in male Wistar rats?
Cannabinoid O-2545 demonstrates therapeutic potential in mitigating amiodarone-induced pulmonary toxicity and fibrosis in an in vivo rat model.
Should not yet change practice for amiodarone-treated patients; leaves open therapeutic potential of O-2545 in pulmonary fibrosis.
Introduction: Amiodarone (AMIO) is one of the most prescribed antiarrhythmic medications and is commonly used to treat atrial and ventricular fibrillations. A notable adverse effect of AMIO is pulmonary fibrosis. Cannabinoid (O-2545) has been shown to exert antioxidant, anti-inflammatory, and antifibrotic effects in both in vivo and in vitro experimental models. The present study aimed to investigate whether cannabinoid (O-2545) may attenuate amiodarone-induced pulmonary fibrosis in male Wistar rats. Methods: A regimen of 50 mg/kg AMIO was administered via oral gavage daily for 10 consecutive days to induce acute pulmonary fibrosis. The experiment included 24 Wistar rats assigned to four groups. The control group received daily subcutaneous injections of normal saline for the same time period. The AMIO group received a daily oral gavage of AMIO (50 mg/kg) for 10 days. Concurrently, the O-2545 group received daily oral doses of cannabinoid. The combined treatment group received both AMIO and cannabinoid orally each day for 10 days. Results: High-dose AMIO (50 mg/kg) administration resulted in a significant elevation of oxidative stress, followed by a decrease in antioxidant function, an increase in inflammatory cytokines, fibrosis markers, and apoptosis. Pro-inflammatory cytokines tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β) and adenosine (Adens), apoptotic markers tumor protein p53 (p53) and caspase 3 protein (caspase-3), oxidative stress malondialdehyde (MDA), fibrosis indicator hydroxyproline (HYDROX), and histone deacetylase (HDAC) activity, accompanied by a marked reduction in the antioxidant glutathione (GSH), compared to the control group. Histopathological examination of pulmonary tissues revealed that O-2545 significantly mitigated AMIO-induced pulmonary fibrosis. In conclusion, the results showed that cannabinoid (O-2545) may offer significant therapeutic potential in mitigating pulmonary toxicity induced by AMIO in rats. Purpose: This study investigates the possible protective therapeutic effects of (O-2545) on AMIO-induced pulmonary fibrosis in Wistar rats.
No takes yet. Share an insight, caveat, or question.
Riyadh S. Almalki (2026) studied this question. null.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: